Fibrosis
Pulmonary fibrosis is a condition in which the tissue deep in your lungs becomes scarred over time. This tissue gets thick and stiff. That makes it hard for you to catch your breath, and your blood may not get enough oxygen.
Causes of pulmonary fibrosis include environmental pollutants, some medicines, some connective tissue diseases, and interstitial lung disease. Interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. In most cases, the cause cannot be found. This is called idiopathic pulmonary fibrosis.
Symptoms include:
- Shortness of breath
- A dry, hacking cough that doesn't get better
- Fatigue
- Weight loss for no known reason
- Aching muscles and joints
- Clubbing, which is the widening and rounding of the tips of the fingers or toes
Your doctor may use your medical history, imaging tests, a biopsy, and lung function tests to diagnose pulmonary fibrosis. There is no cure. Treatments can help with symptoms and improve your quality of life. They include medicines, oxygen therapy, pulmonary rehabilitation, or a lung transplant.
NIH: National Heart, Lung, and Blood Institute
Fibrosis FDA Approved Drugs
BETHKIS [TobramycinC18H37N5O9]
RX
- 300mg/4ml (inhalation solution)
Chiesi Usa IncOct 12, 2012
- Management of cystic fibrosis patients.
CAYSTON [AztreonamC13H17N5O8S2]
RX
- 75mg/vial (inhalation for solution)
GileadFeb 22, 2010
- Improve respiratory symptoms in cystic fibrosis in patients with pseudomonas aeruginosa.
JAKAFI [Ruxolitinib PhosphateC17H18N6H3O4P]
RX
- eq 10mg base (oral tablet)
eq 15mg base (oral tablet)
eq 20mg base (oral tablet)
eq 25mg base (oral tablet)
eq 5mg base (oral tablet)
Incyte CorpNov 16, 2011
- For the treatment of intermediate or high-risk myelofibrosis.
- For the treatment of polycythemia vera.
- Use of ruxolitinib (jakafi) for blocking signal transduction of janus associated kinases (jaks) jak1 and/or jak2.
- Use of ruxolitinib (jakafi) for inhibiting janus associated kinases (jaks) jak1 and/or jak2..
KALYDECO [IvacaftorC24H28N2O3]
RX
- 150mg (oral tablet)
50mg/packet (oral granule)
75mg/packet (oral granule)
Vertex PharmsJan 31, 2012
Vertex Pharms IncMar 17, 2015
Vertex Pharms IncMar 17, 2015
- Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide.
- Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide.
- Method of treating cystic fibrosis.
OFEV [Nintedanib EsylateC31H33N5O4C2H6O3S]
RX
- eq 100mg base (oral capsule)
eq 150mg base (oral capsule)
Boehringer IngelheimOct 15, 2014
- Treatment of idiopathic pulmonary fibrosis (ipf).
ORKAMBI [IvacaftorC24H28N2O3 : LumacaftorC24H18F2N2O5]
RX
- 125mg : 100mg (oral tablet)
125mg : 200mg (oral tablet)
Vertex Pharms IncSep 28, 2016
- Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using a dosage unit as defined in claim 1 of u.s. patent no. 9,192,606.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and form i lumacaftor.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor.
- Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338.
- Method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.
- Method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene..
- Method of treating cystic fibrosis using n-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide and 3-(6-(1-2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid.
- Method of treating cystic fibrosis.
TOBI PODHALER [TobramycinC18H37N5O9]
RX
- 28mg (inhalation powder)
NovartisMar 22, 2013
- Treatment of cystic fibrosis patients with pseudomonas aeruginosa.
ZENPEP [Pancrelipase (amylase : Lipase : Protease)]
RX
- 109,000usp units : 20,000usp units : 68,000usp units (oral capsule, delayed release)
136,000usp units : 25,000usp units : 85,000usp units (oral capsule, delayed release)
16,000usp units : 3,000usp units : 10,000usp units (oral capsule, delayed release)
218,000usp units : 40,00usp units : 136,000 usp units (oral capsule, delayed release)
27,000usp units : 5,000usp units : 17,000usp units (oral capsule, delayed release)
55,000usp units : 10,000usp units : 34,000usp units (oral capsule, delayed release)
82,000usp units : 15,000usp units : 51,000usp units (oral capsule, delayed release)
Forest Labs IncAug 27, 2009
- Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.
WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.
Home Remedies for Fibrosis
SCAR REDUCTION [fibrosis]
Apply coconut oil, cocoa butter, castor oil or vitamin E oil as soon as the wound closes.Jlaiii | August 12th, 2020
Apply coconut oil, cocoa butter, castor oil or vitamin E oil as soon as the wound closes.Jlaiii | August 12th, 2020
References
1) Bergner, Pal., Griswold, Alexandra F., Hufford, David J., et al. . Morton Grove, Il: Publications International, 2017.